If you made any changes in Pure these will be visible here soon.

Personal profile

Education

  • 1985-1989 Ph.D., Graduate Institute of Medical Sciences, National Defense Medical Center
  • 1976-1983 M.D., School of Medicine, National Defense Medical Center

Experience

  • 2018.11- Deputy Director, Taipei Cancer Center, Taipei Medical University
  • Director, Division of Oncology, Department of Internal Medicine, College of Medicine, Taipei Medical University
  • 2018.02- Professor, International Master/Ph.D. Program in Medicine, College of Medicine, Taipei Medical University
  • 2016.11-2017.10 Professor, International Master/Ph.D. Program in Medicine, College of Medicine, Taipei Medical University
  • 2015.10-2019.07.31 Deputy Director, Department of Human Research, Taipei Medical University
  • 2015.02- Chief, Department of Medical Affairs, Shuang Ho Hospital, Taipei Medical University
  • 2014.02-2016.07 Director, Joint Clinical Research Center, Taipei Medical University
  • 2010.10- Chief and Professor, Division of Hematology/Oncology, Shuang-Ho Hospital, Taipei Medical University, 
  • 2010.10-2015.01 Chief and Professor, Division of Internal Medicine, Shuang-Ho Hospital, Taipei Medical University, Taipei, Taiwan
  • 2010.09- Professor, Graduate Institute of Clinical Medicine, Taipei Medical University
  • 2010.05- Director, Division of Oncology, Tri-Service General Hospital
  • 1997.08-2010.09 Chief and Professor, Division of Hematology/Oncology, Tri-Service General Hospital, National Defense Medical Center,
  • 1992.08-2010.09 Attending Physician, Division of Hematology/Oncology, Tri-Service General Hospital
  • 1989.07-1997.07 Associate Professor, National Defense Medical Center
  • 1987-1789 Research Fellow, Department of Immunology and Biochemistry Research, Roswell Park Memorial Institute,
  • 1983.08-1992.07 Resident, Chief Resident, Fellow, Department of Medicine, Tri-Service General Hospital, National Defense Medical Center
  • 1983.08-1989.06 Teaching Assistant, National Defense Medical Center

Awards

  • 2019 Distinguished Clinical Trial Leader Award, Taipei Medical University
  • 2008 The best 100 physicians of Taiwan
  • 2005 Teacher of the year, National Defense University
  • 2001 Remarkable physician of Tri-Service General Hospital
  • 2000 Teacher of the year, National Defense Medical Center. September
  • 1998 Decent Man, Tri-Service General Hospital
  • 1997 International Who's Who of Contemporary Achievement, Hall of Fame, awarded by the American Biographical Institute
  • 1996 Men of Achievement, 17th edition, published by The International Biographical Center, Cambridge, England
  • 1994 Outstanding Military Physician honored by the Ministry of Defense, Taiwan, R. O. C.
  • 1994-1995 Scholarship of Biomedical Science for physician awarded by Academia Sinica, Taiwan, R. O. C.
  • 1993 Distinguished Youth of Taipei City
  • 1992 Remarkable physician of Tri-Service General Hospital
  • 1989 First class Academic Medal, awarded by Ministry of Defense, R. O. C.
  • 1983 Second class Academic Medal, awarded by Ministry of Defense, R. O. C.

Research Interests

  • Dr. Chao’s current researchinterests focus on clinical trials and translational studies. The clinical trials he involves are about the development of new drugs or strategies in treating cancers and hematological disorders. In translational studies, his major effort is on the development of a novel biochemical marker, i.e. tartrate-resistant acid phosphatase 5b, in the diagnosis and monitoring of metastatic bone disease of breast cancer. He also intends to define the role and search the potential usefulness of tartrate-resistant acid phosphatase 5a in macrophage-related disorders.

Fingerprint Dive into the research topics where Tsu-Yi Chao is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 33 Similar Profiles

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Projects

Research Output

  • 4679 Citations
  • 27 h-Index
  • 199 Article
  • 2 Comment/debate
  • 1 Letter
  • 1 Review article

Ovatodiolide suppresses oral cancer malignancy by down-regulating exosomal mir-21/STAT3/β-catenin cargo and preventing oncogenic transformation of normal gingival fibroblasts

Chen, J. H., Wu, A. T. H., Bamodu, O. A., Yadav, V. K., Chao, T. Y., Tzeng, Y. M., Mukhopadhyay, D., Hsiao, M. & Lee, J. C., Jan 2020, In : Cancers. 12, 1, 56.

Research output: Contribution to journalArticle

Open Access
  • 2 Citations (Scopus)
    Open Access
  • An Open-Label, Multicenter, Phase I, Dose Escalation Study with Phase II Expansion Cohort to Determine the Safety, Pharmacokinetics, and Preliminary Antitumor Activity of Intravenous TKM-080301 in Subjects with Advanced Hepatocellular Carcinoma

    El Dika, I., Lim, H. Y., Yong, W. P., Lin, C. C., Yoon, J. H., Modiano, M., Freilich, B., Choi, H. J., Chao, T. Y., Kelley, R. K., Brown, J., Knox, J., Ryoo, B. Y., Yau, T. & Abou-Alfa, G. K., Jan 1 2019, (Accepted/In press) In : Oncologist.

    Research output: Contribution to journalArticle

    Open Access
  • 13 Citations (Scopus)
    Open Access
  • 2 Citations (Scopus)

    Antrocin, a bioactive component from Antrodia cinnamomea, suppresses breast carcinogenesis and stemness via downregulation of β-catenin/Notch1/Akt signaling

    Chen, J. H., T.H Wu, A., T.W Tzeng, D., Huang, C. C., Tzeng, Y. M. & Chao, T. Y., Jan 1 2019, In : Phytomedicine. 52, p. 70-78 9 p.

    Research output: Contribution to journalArticle

  • 3 Citations (Scopus)